Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | DTYMK | P23919 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | NAMPT | P43490 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 1/20 | 0.42 |
| ▸ | FNTB | P49356 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22521307 | 0.86 | GPR119 (0.47) | POLBGPR119OPRD1OPRK1CYP11B2 | |
| SCHEMBL29609790 | 0.85 | MAPK1 (0.51) | GPR119OPRD1OPRK1MAPK1CYP11B2 | |
| SCHEMBL23902054 | 0.85 | MAPK1 (0.51) | GPR119OPRD1OPRK1MAPK1CYP11B2 | |
| SCHEMBL22770359 | 0.82 | POLB (0.47) | POLBGPR119OPRD1OPRK1MAPK1 | |
| SCHEMBL29930648 | 0.81 | SPR (0.42) | MAPK1CYP3A4CYP2D6HSD17B10TSHR | |
| SCHEMBL13005000 | 0.80 | CYP11B2 (0.43) | POLBGPR119OPRD1OPRK1CYP11B2 | |
| SCHEMBL21856202 | 0.79 | POLB (0.48) | POLBGPR119OPRD1OPRK1MAPK1 | |
| SCHEMBL30207681 | 0.79 | POLB (0.55) | POLBGPR119MAPK1DTYMKMAPT | |
| SCHEMBL23024346 | 0.78 | NAMPT (0.48) | POLBGPR119OPRD1OPRK1NAMPT | |
| SCHEMBL31317561 | 0.78 | NAMPT (0.59) | GPR119CYP11B2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4227307-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | Genzyme Corporation (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023114954-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | GENZYME CORPORATION (US) | 2023-06-22 | — | — | WO | disclosed |
| EP-4129987-A1 | CRYSTAL FORM OF FREE ALKALI OF NITROGEN-CONTAINING AROMATIC DERIVATIVES | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2023-02-08 | — | — | EP | disclosed |
| WO-2023282702-A1 | SHP2 INHIBITOR AND USE THEREOF | 주식회사 카나프테라퓨틱스 | 2023-01-12 | — | — | WO | disclosed |
| WO-2022063190-A1 | PYRAZINE THIOBIPHENYL COMPOUND AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2022-03-31 | — | — | WO | disclosed |
| WO-2021197452-A1 | CRYSTAL FORM OF FREE ALKALI OF NITROGEN-CONTAINING AROMATIC DERIVATIVES | 上海翰森生物医药科技有限公司 | 2021-10-07 | — | — | WO | disclosed |
| US-20100317679-A1 | SUBSTITUTED ARYL-FUSED SPIROCYCLIC AMINES | LIGAND PHARMACEUTICALS, INC. (US) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317679-A1 | SUBSTITUTED ARYL-FUSED SPIROCYCLIC AMINES | HRH3, HRH4, HRH2 | POLB 4334/4885GPR119 200/4885OPRD1 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.